The cost-effectiveness of transcatheter aortic valve implantation: exploring the Italian National Health System perspective and different patient risk groupsEUROPEAN JOURNAL OF HEALTH ECONOMICSIF32021-05-218OAAI
THE COST-EFFECTIVENESS OF TRANSCATHETER AORTIC VALVE IMPLANTATION: EXPLORING THE ITALIAN NATIONAL HEALTH SYSTEM PERSPECTIVE AND CONSIDERING DIFFERENT PATIENTS RISK GROUPSVALUE IN HEALTHIF62018-10-010OAAI
COST CONSEQUENCE ANALYSIS OF SITAGLIPTIN plus METFORMIN VS SULFONYLUREAS plus METFORMIN IN TYPE 2 DIABETIC PATIENTS IN ITALYVALUE IN HEALTHIF62016-11-010OAAI
BUDGET IMPACT ANALYSIS OF THE USE OF EXTENDED HALF-LIFE RECOMBINANT FACTOR VIII (EFMOROCTOG ALFA) FOR THE TREATMENT OF CONGENITAL HAEMOPHILIA A: THE ITALIAN NATIONAL HEALTH SYSTEM PERSPECTIVEVALUE IN HEALTHIF62016-11-010OAAI
THE COST OF ILLNESS OF ULTRA-RARE CRYOPYRIN ASSOCIATED PERIODIC SYNDROMES (CAPS) IN ITALY: PRELIMINARY RESULTS FROM THE RADICEA PROJECTVALUE IN HEALTHIF62016-11-011PREAI
INCREASED COST-EFFECTIVENESS OF DIAGNOSTIC IMAGING IN PATIENTS WITH SUSPECTED CAD BY USING A NEW CLINICAL-BIOHUMORAL PREDICTIVE MODEL OF DISEASEVALUE IN HEALTHIF62015-11-010OAAI
AN IN SILICO HEALTH ECONOMIC MODEL APPLIED TO CRYOPYRIN ASSOCIATED PERIODIC SYNDROMES (CAPS): COST EFFECTIVENESS OF PREVENTION EFFECTS OF ULTRA-ORPHAN DRUGS FOR RARE DISEASESVALUE IN HEALTHIF62015-11-010OAAI
THE OPPORTUNITY OF TREATING TYPE II DIABETES WITH DPP4I: AN ECONOMIC EVALUATION VERSUS CONVENTIONAL TREATMENT IN THE ITALIAN SETTINGVALUE IN HEALTHIF62014-11-010OAAI
COST-EFFECTIVENESS (CE) OF IMAGING-GUIDED STRATEGIES FOR THE DIAGNOSIS OF CORONARY ARTERY DISEASE (CAD): RESULTS FROM THE EVINCI STUDYVALUE IN HEALTHIF62014-11-010OAAI
EFFECTIVENESS AND COSTS OF DIFFERENT STRATEGIES FOR THE DIAGNOSIS OF STABLE CORONARY ARTERY DISEASE RESULTS FROM THE EVINCI STUDYVALUE IN HEALTHIF62014-11-012OAAI
A BUDGET IMPA CT ANALYSIS (BIA) OF THE USE OF PARICALCITOL FOR THE TREATMENT OF SECONDARY HYPERPARATHYROIDISM (SHPT) IN END STAGE RENAL DISEASE PATIENTSVALUE IN HEALTHIF62014-11-011OAAI
EARLY TIMING OF THE USE OF PARICALCITOL FOR THE TREATMENT OF SECONDARY HYPERPARATHYROIDISM (SHPT) IN CHRONIC KIDNEY PATIENTS (CKD): A BUDGET IMPACT ANALYSIS (BI)VALUE IN HEALTHIF62014-05-010OAAI